2 results
Approved WMORecruiting
The objective of this prospective, observational study is to ensure the safety and the wellbeing of subjects treated with the NEVO* SES.
Approved WMORecruiting
This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 as a single agent (Phase Ia) or in combination with a checkpoint inhibitor targeting the PD-L1/PD-1 axis (Phase Ib) in patients with locally advanced or…